Moderna Outlined Manufacturing Strategy in Milan
The pharmaceutical firm detailed its supply chain approach during the CPHI conference held this week in Italy.
Updated on Oct. 7, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to manage the complex manufacturing of next-generation medical treatments?
Michelle Rodriguez presented Moderna's hybrid manufacturing model at the CPHI Milan 2026 conference. The strategy balances internal drug substance production with external partnerships to ensure supply chain security.
Why it matters
Moderna is adapting its operational strategy following a period of declining revenues and reduced federal backing for mRNA research. Maintaining internal manufacturing capacity remains a key pillar of the company's effort to stabilize its supply chain.
Moderna recorded $1.9 billion in revenue for 2025, representing a 40% year-on-year decline. This follows the high-growth years of Spikevax, which reached $18.4 billion in sales in 2022.
The players
Michelle Rodriguez
She is a spokesperson for Moderna who presented the firm's manufacturing strategy at the 2026 CPHI conference.
Moderna
Headquartered in Cambridge, Massachusetts, this biotechnology company specializes in mRNA-based vaccines and therapies.
The details
Moderna employs a dual-track manufacturing strategy, keeping drug substance production in-house while relying on contract development and manufacturing organizations for drug product and final packaging. The company manages these operations through a network of international centers, including new capacity added in the UK in 2025.
Timeline
Spikevax achieved initial regulatory approval in 2021.
The RSV vaccine mRESVIA gained US and European approval in 2024.
The US government cut funding for 20 mRNA projects in 2025.
The influenza vaccine Mflusiva received regulatory approval in 2026.
The CPHI Milan conference takes place from October 6 to October 8, 2026.
Market Landscape
The firm is adjusting its reliance on external partnerships in the wake of the 2025 US government federal funding cuts for mRNA vaccine projects. This shift positions Moderna to consolidate its supply chain while competing with larger legacy pharmaceutical manufacturers.
Consumers can expect Moderna to continue rolling out its recently approved RSV and influenza vaccines across global markets. The company's focus on supply chain security aims to prevent potential future product shortages.
The takeaway
Moderna is shifting toward a leaner, more resilient manufacturing model to navigate a post-pandemic market with fewer federal subsidies. Investors and patients should watch how this hybrid approach impacts the rollout speed of the company's new influenza and RSV products.
Further reading
For more on the current state of vaccine production and industry trends, visit the Healthcare section.
Source note: This article includes information reported by Pharmaceutical Technology.
Live Poll
Do you trust pharmaceutical companies to manage the complex manufacturing of next-generation medical treatments?
